ENDONOVO THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum
ENDONOVO THERAPEUTICS, INC. (ENDV) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum of 2.28% for the 12-month period ending 2019-12-31, per its 10-K filed 2020-05-04.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum · last filed 2020-05-04
- ENDONOVO THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2017-09-30 was 1.31%, a 122.03% increase year-over-year.
- ENDONOVO THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2017-06-30 was 1.79%, a 68.87% increase year-over-year.
- ENDONOVO THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2017-03-31 was 1.06%, a 0.00% change year-over-year.
- ENDONOVO THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2016-09-30 was 0.59%.
- ENDONOVO THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2019 was 2.28%, a 10.68% increase from fiscal 2018.
- ENDONOVO THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2018 was 2.06%, a 15.08% increase from fiscal 2017.
- ENDONOVO THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2017 was 1.79%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 12 month |
|---|---|---|---|---|
| 2019-12-31 | 2.28% 10-K · filed 2020-05-04 | |||
| 2018-12-31 | 2.06% 10-K · filed 2020-05-04 | |||
| 2017-12-31 | 1.79% 10-K · filed 2019-04-15 | |||
| 2017-09-30 | 1.31% 10-Q/A · filed 2017-11-09 | 1.31% 10-Q/A · filed 2017-11-09 | ||
| 2017-06-30 | 1.79% 10-Q · filed 2017-08-10 | 1.79% 10-Q · filed 2017-08-10 | ||
| 2017-03-31 | 1.06% 10-Q · filed 2017-05-12 | |||
| 2016-09-30 | 0.59% 10-Q/A · filed 2017-11-09 | 1.06% 10-Q/A · filed 2017-11-09 | ||
| 2016-06-30 | 1.06% 10-Q · filed 2017-08-10 | 1.06% 10-Q · filed 2017-08-10 | ||
| 2016-03-31 | 1.06% 10-Q · filed 2017-05-12 |